EoE Behaves As a Unique Th2 Disease: a Narrative Review

Overview

Journal Transl Gastroenterol Hepatol

Publisher AME Publishing Company

Specialty Gastroenterology

Date 2023 Jan 27

PMID 36704651

Authors

Simon S Rabinowitz

Liwei Yu

Patrick Geraghty

Affiliations

Soon will be listed here.

Abstract

Background And Objective: To highlight and interpret two significant differences between eosinophilic esophagitis (EoE), a type 2 helper cell (Th2) disease, and three other representative Th2 diseases. EoE, asthma, atopic dermatitis (AD), chronic rhinosinusitis (CRS) and other Th2 diseases employ epithelial alarmins to recognize triggers, share a prototypical inflammatory cascade, and respond to glucocorticoids. However, EoE also has several distinguishing characteristics which may be explained by a distinct pathophysiologic mechanism.

Methods: The following report consist of four related narrative reviews which combine comprehensive PubMed and Google searches. Two reviews were performed to identify and contrast all eligible studies describing serologic markers in EoE compared to asthma, AD, and CRS. Two additional reviews then compare the responses to parenteral biological therapies in EoE and in the same representative Th2 diseases.

Key Content And Findings: Comprehensive literature searches definitively differentiate the absence of serologic markers in EoE compared to their identification in the other representative Th2 diseases. Similarly, a summary of therapeutic trials demonstrates that while EoE is unable to clinically respond to a variety of parenteral biological therapies, asthma, AD and CRS are very effectively treated with this same approach. A novel pathophysiology for EoE is proposed, and the emerging literature that support its existence is summarized.

Conclusions: The fundamental properties described in this narrative regarding serologic signaling and response to parenteral therapy in EoE could be explained if EoE employs a unique application of the Th2 pathway. One potential mechanism consistent with these observations is that EoE employs exclusively esophageal mucosal constituents to initiate and generate the prototypical Th2 cascade and the fibrostenotic changes that follow.

Citing Articles

EFNB1 drives glioma progression and shapes the immune microenvironment: a potential prognostic biomarker.

Zheng Y, Shi J Discov Oncol. 2025; 16(1):249.

PMID: 40014231 PMC: 11868007. DOI: 10.1007/s12672-025-01867-y.

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.

Ridolo E, Barone A, Ottoni M, Peveri S, Montagni M, Nicoletta F Int J Mol Sci. 2024; 25(3).

PMID: 38338983 PMC: 10855546. DOI: 10.3390/ijms25031702.

Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms.

Massironi S, Mulinacci G, Gallo C, Elvevi A, Danese S, Invernizzi P Cells. 2023; 12(20).

PMID: 37887317 PMC: 10605530. DOI: 10.3390/cells12202473.

Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.

Kim B, Rothenberg M, Sun X, Bachert C, Artis D, Zaheer R J Allergy Clin Immunol. 2023; 153(4):879-893.

PMID: 37634890 PMC: 11215634. DOI: 10.1016/j.jaci.2023.08.017.

References

Ho J, Earls P, Harvey R . Systemic biomarkers of eosinophilic chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2019; 20(1):23-29. DOI: 10.1097/ACI.0000000000000602. View

Ho J, Li W, Grayson J, Alvarado R, Rimmer J, Sewell W . Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis. Rhinology. 2020; 59(1):59-65. DOI: 10.4193/Rhin20.073. View

Rothenberg M, Spergel J, Sherrill J, Annaiah K, Martin L, Cianferoni A . Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet. 2010; 42(4):289-91. PMC: 3740732. DOI: 10.1038/ng.547. View

Lu S, Herzlinger M, Cao W, Noble L, Yang D, Shapiro J . Utility of 15(S)-HETE as a Serological Marker for Eosinophilic Esophagitis. Sci Rep. 2018; 8(1):14498. PMC: 6162315. DOI: 10.1038/s41598-018-32944-8. View

Ma S, Zhang L . Elevated serum OX40L is a biomarker for identifying corticosteroid resistance in pediatric asthmatic patients. BMC Pulm Med. 2019; 19(1):66. PMC: 6423878. DOI: 10.1186/s12890-019-0819-5. View

Dellon E, Rusin S, Gebhart J, Covey S, Higgins L, Beitia R . Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study. Am J Gastroenterol. 2015; 110(6):821-7. PMC: 4578703. DOI: 10.1038/ajg.2015.57. View

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

Greuter T, Hirano I, Dellon E . Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol. 2019; 145(1):38-45. PMC: 6981295. DOI: 10.1016/j.jaci.2019.10.027. View

Guttman-Yassky E, Brunner P, Neumann A, Khattri S, Pavel A, Malik K . Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018; 78(5):872-881.e6. PMC: 8711034. DOI: 10.1016/j.jaad.2018.01.016. View

10.

Koh G, Shek L, Goh D, van Bever H, Koh D . Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2006; 101(4):696-705. DOI: 10.1016/j.rmed.2006.08.012. View

11.

Min S, Nylund C, Baker T, Ally M, Reinhardt B, Chen Y . Longitudinal Evaluation of Noninvasive Biomarkers for Eosinophilic Esophagitis. J Clin Gastroenterol. 2016; 51(2):127-135. DOI: 10.1097/MCG.0000000000000621. View

12.

Tiotiu A . Biomarkers in asthma: state of the art. Asthma Res Pract. 2019; 4:10. PMC: 6302401. DOI: 10.1186/s40733-018-0047-4. View

13.

Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A . Periostin: An emerging biomarker for allergic diseases. Allergy. 2019; 74(11):2116-2128. DOI: 10.1111/all.13814. View

14.

Hirano I, Collins M, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A . RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology. 2018; 156(3):592-603.e10. DOI: 10.1053/j.gastro.2018.10.051. View

15.

Sarbinowska J, Wiatrak B, Wasko-Czopnik D . Searching for Noninvasive Predictors of the Diagnosis and Monitoring of Eosinophilic Esophagitis-The Importance of Biomarkers of the Inflammatory Reaction Involving Eosinophils. Biomolecules. 2021; 11(6). PMC: 8232675. DOI: 10.3390/biom11060890. View

16.

Wollenberg A, Howell M, Guttman-Yassky E, Silverberg J, Kell C, Ranade K . Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2018; 143(1):135-141. DOI: 10.1016/j.jaci.2018.05.029. View

17.

Markowitz J, Jobe L, Miller M, Frost C, Laney Z, Eke R . Safety and Efficacy of Reslizumab for Children and Adolescents With Eosinophilic Esophagitis Treated for 9 Years. J Pediatr Gastroenterol Nutr. 2017; 66(6):893-897. DOI: 10.1097/MPG.0000000000001840. View

18.

Sears M, Burrows B, Flannery E, Herbison G, Hewitt C, Holdaway M . Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med. 1991; 325(15):1067-71. DOI: 10.1056/NEJM199110103251504. View

19.

Kabashima K, Furue M, Hanifin J, Pulka G, Wollenberg A, Galus R . Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142(4):1121-1130.e7. DOI: 10.1016/j.jaci.2018.03.018. View

20.

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View